Bausch Health Companies Inc. (TSX:BHC)
7.89
-0.28 (-3.43%)
Aug 1, 2025, 4:00 PM EDT
Bausch Health Companies Revenue
In the year 2024, Bausch Health Companies had annual revenue of $9.63B USD with 9.91% growth.
Revenue
$9.63B
Revenue Growth
+9.91%
P/S Ratio
n/a
Revenue / Employee
$464.98K
Employees
20,700
Market Cap
2.91B CAD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.63B | 868.00M | 9.91% |
Dec 31, 2023 | 8.76B | 633.00M | 7.79% |
Dec 31, 2022 | 8.12B | -310.00M | -3.68% |
Dec 31, 2021 | 8.43B | 407.00M | 5.07% |
Dec 31, 2020 | 8.03B | -574.00M | -6.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Green Thumb Industries | 1.64B |
Sienna Senior Living | 896.45M |
dentalcorp Holdings | 1.58B |
Curaleaf Holdings | 1.89B |
Trulieve Cannabis | 1.71B |
WELL Health Technologies | 990.34M |
Cronos Group | 179.08M |
Extendicare | 1.47B |
Bausch Health Companies News
- 2 days ago - Bausch Health Companies Inc. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 2 days ago - Bausch Health reaffirms 2025 revenue target of $4.95B–$5.1B as debt reduction and pipeline expansion advance - Seeking Alpha
- 2 days ago - Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Bausch Health Companies GAAP EPS of $0.40 beats by $0.36, revenue of $2.53B beats by $40M - Seeking Alpha
- 2 days ago - Bausch Health Announces Second Quarter 2025 Results - Accesswire
- 3 days ago - Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout - Benzinga
- 3 days ago - Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout - Benzinga
- 3 days ago - Bausch Health to acquire liver drug developer Durect for $1.75 per share - Seeking Alpha